Cantor Fitzgerald Reiterates Neutral on Amedisys, Maintains $101 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on Amedisys (NASDAQ:AMED) and maintained a price target of $101.
July 25, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated a Neutral rating on Amedisys and maintained a price target of $101.
The reiteration of a Neutral rating and maintenance of the price target at $101 suggests that the analyst does not foresee significant short-term changes in the stock's performance. This is likely to result in a neutral impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100